RxDoctor Payments Data

Maen Abou Ziki, MD

Clinical Cardiac Electrophysiology · Newport News, VANPI 1720499833

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $22,120 of the $35,146 with a category attached, or 62.9%. 17 manufacturers reported payments, led by Biotronik Inc. at 56.9% of the total.

$35,146in general payments, 2019–2025

Across 224 payments — averaging $156.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$20K
  • Medtronic$8K
  • Boston Scientific$3K
  • Philips North America LLC$1K
  • Medical Device Business Services, Inc.$654
  • Biosense Webster, Inc.$404
  • plus $1K from 11 others
$4,713in research payments, 2019–2025

Across 1 payment — averaging $4712.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$5K

What the payments were for

  • Consulting fees$2,0006%
  • Grants$1,0003%
  • Travel & lodging$22,12063%
  • Food & beverage$9,22626%
  • Education$8002%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,146 in reported general payments places this provider in the 65th percentile of 90 clinical cardiac electrophysiology providers in Virginia.

See all clinical cardiac electrophysiology providers in Virginia

Medicare billing

Part B allowed, 2024
$296,343
Medicare patients
686
Services billed
4,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban227$221,942
XareltoRivaroxaban40$47,532
Metoprolol Succinate314$3,652
Amiodarone Hcl168$2,928
Mexiletine Hcl35$2,465
Flecainide Acetate66$1,917
Dofetilide12$1,815
Diltiazem 24hr Er (La)Diltiazem Hcl11$1,024
PaceroneAmiodarone Hcl13$772
Diltiazem 24hr Er (Cd)Diltiazem Hcl37$655
Potassium Chloride31$568
Carvedilol69$425
SotalolSotalol Hcl20$168
Warfarin Sodium30$152
Amlodipine Besylate20$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$93$221,942227 claims
Johnson & JohnsonXarelto$19$47,53240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 90 clinical cardiac electrophysiology providers in Virginia.

Other clinical cardiac electrophysiology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →